Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib in Recurrent Glioblastoma
NCT00777153Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2008
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of cediranib in glioblastoma (GBM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression Free Survival. Started Oct 2008; status: completed.
02
Drugs
cediranib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00777153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777153.